Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD
Financial writer discusses Coya Therapeutics, Inc.'s Treg therapies for neurodegenerative diseases like ALS, FTD, and PD.
Who won the Destiny 2 Sundered Doctrine World First dungeon race?
After two intense races in 2024, the first competition of 2025 in Destiny 2 is the Sundered Doctrine World First dungeon race. Teams of three Guardians around the globe will queue up at the same time ...
Neurocrine Biosciences targets $2.5B-$2.6B INGREZZA sales for 2025 amid expanded sales force
CFO Matt Abernethy projected INGREZZA sales for 2025 to range between $2.5 billion and $2.6 billion, reflecting $250 million growth at the midpoint. He noted increased competitive pressure and payer ...
News-Press NOW6d
Designs unveiled for replacement of Baltimore bridge almost a year after deadly collapse
Almost a year after the deadly collapse of Baltimore’s Francis Scott Key Bridge, Maryland officials on Tuesday unveiled their ...